Hepion Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
John Brancaccio
Chief executive officer
US$81.0k
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | 0.006% |
Management average tenure | no data |
Board average tenure | 2yrs |
Recent management updates
Recent updates
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely
Aug 10We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Apr 25We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Oct 27Hepion Pharma rises as company begins NASH treatment trial
Aug 31Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?
Jul 04Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH
Feb 17Hepion Pharmaceuticals: Facing The Momentous Year 2022
Jan 21Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep 21Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth
Sep 14Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Sep 08Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)
May 26What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?
Feb 18Hepion Pharma cleared to advance final dosing cohort in NASH trial
Dec 29Hepion Pharma to begin CRV431 testing in COVID-19 patients
Dec 22Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study
Dec 10Hepion Pharma prices equity offering at $1.50
Nov 25Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
Oct 31CEO
John Brancaccio (76 yo)
less than a year
Tenure
US$81,000
Compensation
Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Interim CEO | 11.4yrs | US$81.00k | 0.0060% $ 224.1 | |
Independent Director | 10.9yrs | US$72.90k | 0.0060% $ 224.1 | |
Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
Scientific Advisory Board Chair | 5.2yrs | no data | no data | |
Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
Independent Director | less than a year | no data | no data | |
Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
Independent Director | 2.3yrs | US$80.50k | no data |
2.0yrs
Average Tenure
68yo
Average Age
Experienced Board: HEPA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.